BDSX BIODESIX INC
Services-Medical Laboratories · Nasdaq · SEC CIK 1439725 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY31.2%
TTM net income YoY31.5%
TTM EPS YoY49.0%
Revenue 3-yr CAGR33.7%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-18.7%
Net margin-25.7%
FCF margin-18.1%
EBITDA margin-13.4%
Returns
ROE-778.9%
ROA-29.6%
ROIC (approx.)-50.2%
Asset turnover1.15x
Leverage & solvency
Liabilities / assets90.8%
Debt / equity5.76x
Current ratio2.96x
Interest coverage-2.45x
Cash quality & payout
Operating cash flow / net income0.67x
Accruals ratio-9.8%
Payout ratio—
Capex / revenue0.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $88.50M | $71.32M |
| R&D expense | $12.00M | $9.56M |
| SG&A expense | $87.55M | $80.45M |
| Operating income | -$27.87M | -$34.50M |
| Interest expense | $7.72M | $8.26M |
| Income tax | $0 | $0 |
| Net income | -$35.27M | -$42.93M |
| EBITDA | -$22.20M | -$28.73M |
| EPS (basic) | -4.67 | -6.64 |
| EPS (diluted) | -4.67 | -6.64 |
| Weighted avg. shares (diluted) | 7.55M | 6.47M |
| Banking | ||
| Provision for credit losses | $180,000 | $887,000 |
| Balance sheet | ||
| Cash & equivalents | $18.99M | $26.33M |
| Receivables | $9.04M | $8.60M |
| Current assets | $32.52M | $39.48M |
| PP&E, net | $24.82M | $27.83M |
| Goodwill | $15.03M | $15.03M |
| Intangibles | $3.88M | $5.87M |
| Total assets | $87.48M | $97.24M |
| Current liabilities | $17.44M | $14.32M |
| Long-term debt | $50.01M | $40.03M |
| Total debt | $50.01M | $40.03M |
| Total liabilities | $89.94M | $76.37M |
| Shareholders' equity | -$2.46M | $20.88M |
| Net debt | $31.02M | $13.69M |
| Shares outstanding | 8.25M | 7.27M |
| Cash flow statement | ||
| Operating cash flow | -$23.27M | -$48.65M |
| Capital expenditure | $259,000 | $3.23M |
| Free cash flow | -$23.53M | -$51.88M |
| Investing cash flow | -$403,000 | -$3.44M |
| Financing cash flow | $16.42M | $52.05M |
| Depreciation & amortization | $5.67M | $5.77M |
| Stock-based compensation | $4.14M | $6.64M |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.